Stock GILD GILEAD SCIENCES, INC.
Add to a list

Gilead Sciences, Inc. Share Price

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 23/04/2026 am IST 		After hours 03:16:31 am
132.90 USD -0.29% Intraday chart for Gilead Sciences, Inc. 131.84 -0.80%
21/04 UK's British Land lifts earnings forecast as AI firms flock to London campuses RE
20/04 Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility MT

Valuation: Gilead Sciences, Inc.

Capitalization 17TCr 14TCr 13TCr 12TCr 23TCr 15,51700Cr 23TCr 1,52100Cr 60TCr 7,43300Cr 62TCr 61TCr 26,37100Cr P/E ratio 2026 *
18.1x
P/E ratio 2027 * 16.4x
Enterprise value 17TCr 15TCr 13TCr 13TCr 23TCr 16,05300Cr 24TCr 1,57300Cr 62TCr 7,68900Cr 64TCr 63TCr 27,28100Cr EV / Sales 2026 *
5.66x
EV / Sales 2027 * 5.1x
Free-Float
99.9%
Yield 2026 *
2.47%
Yield 2027 * 2.52%
* Estimated data More valuation ratios

Chart: Gilead Sciences, Inc.

Dynamic Chart

Latest news: Gilead Sciences, Inc.

21/04 UK's British Land lifts earnings forecast as AI firms flock to London campuses RE
20/04 Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility MT
20/04 Arcus Biosciences Discontinues Lung Cancer Trial With Gilead DJ
20/04 Arcus Biosciences Inc - discontinues phase 3 star-121 study with Gilead due to futility RE
17/04 Gilead's Yeztugo Launch Shows Mix of Perspectives, RBC Says MT
17/04 Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating MT
17/04 Gilead Sciences Says All Required Regulatory Approvals Received for Arcellx Acquisition MT
17/04 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating MT
16/04 Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer CI
16/04 Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says MT
15/04 Tango Therapeutics, Inc. Announces Chief Financial Officer Changes CI
15/04 Structure Therapeutics Inc. Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel, Effective April 15, 2026 CI
14/04 Gilead announces PEPFAR & the global fund make additional investment in co's lenacapavir for HIV prevention RE
More news

Last Transcript: Gilead Sciences, Inc.

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. - Special Call
08/04
More transcripts

Analysts' recommendations: Gilead Sciences, Inc.

17/04 Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating MT
17/04 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating MT
13/04 Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating MT
10/04 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating MT
08/04 Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says MT
More recommendations

Press Releases: Gilead Sciences, Inc.

01:36am Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 BU
21/04 Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions PU
17/04 Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer BU
15/04 Our LEN Is Here. Now For Quality Checks in Ireland AQ
14/04 PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access BU
More press releases

News in other languages: Gilead Sciences, Inc.

08/04 Evotec halbiert fast Nettoverlust - zusätzliche Erlöse kurbeln Aktie an
08/04 Aktien New York Schluss: Nahezu stabil vor Ende von Iran-Ultimatum
08/04 Wall Street tussen hoop en vrees terwijl deadline Trump nadert
07/04 Aktien New York: Anleger zurückhaltend vor Ende von Iran-Ultimatum
07/04 Wall Street en repli avant la fin du dernier ultimatum de Trump
More news

Quotes and Performance

1 day-1.09%
1 week-5.38%
Current month-4.64%
1 month-3.14%
3 months+2.94%
6 months+7.11%
Current year+8.28%
More quotes

Course Extremes

1 week 131.34
Extreme 131.34
 140.26
1 month 131.34
Extreme 131.34
 142.97
Current year 116.88
Extreme 116.88
 157.29
1 year 93.37
Extreme 93.37
 157.29
3 years 62.07
Extreme 62.07
 157.29
5 years 57.16
Extreme 57.165
 157.29
10 years 56.56
Extreme 56.56
 157.29
More quotes

Managers and Directors: Gilead Sciences, Inc.

Manager TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 60 01/03/2019
Andrew Dickinson DFI
 Director of Finance/CFO 56 01/11/2019
Keeley Wettan CMP
 Compliance Officer - 18/12/2025
Director TitleAgeSince
Kelly Kramer BRD
 Director/Board Member 58 19/08/2016
Jacqueline Barton BRD
 Director/Board Member 73 01/01/2018
Harish Manwani BRD
 Director/Board Member 72 09/05/2018
More insiders

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-0.29%-5.38%+27.38%+53.52% 17TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+2.04%-0.11%+12.65%+139.20% 81TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.03%-5.83%+44.09%+38.98% 54TCr
ABBVIE INC. Stock AbbVie Inc.
-2.25%-4.64%+17.83%+23.45% 36TCr
ROCHE HOLDING AG Stock Roche Holding AG
-2.28%+0.60%+25.20%+13.86% 32TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
-0.16%-2.56%+43.58%+19.28% 31TCr
NOVARTIS AG Stock Novartis AG
-0.45%-3.91%+27.53%+30.00% 28TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+0.29%-5.89%+45.01%-2.15% 28TCr
AMGEN INC. Stock Amgen Inc.
+0.31%-1.43%+26.40%+41.85% 19TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+0.77%+1.16%-40.89%-57.22% 17TCr
Average -0.27%-2.52%+22.88%+30.08% 34.31TCr
Weighted average by Cap. -0.01%-2.48%+24.75%+48.76%
See all sector performances

Financials

2026 *2027 *
Net sales 3.02TCr 2.58TCr 2.37TCr 2.24TCr 4.13TCr 2,83400Cr 4.22TCr 28TCr 11TCr 1,35800Cr 11TCr 11TCr 4,81700Cr 3.21TCr 2.74TCr 2.51TCr 2.37TCr 4.38TCr 3,00800Cr 4.48TCr 29TCr 12TCr 1,44100Cr 12TCr 12TCr 5,11200Cr
Net income 858.23Cr 732.33Cr 671.72Cr 635.33Cr 1.17TCr 80TCr 1.2TCr 7.89TCr 3.11TCr 39TCr 3.22TCr 3.15TCr 1,36800Cr 1.01TCr 863.52Cr 792.06Cr 749.15Cr 1.38TCr 95TCr 1.41TCr 9.3TCr 3.66TCr 45TCr 3.8TCr 3.72TCr 1,61300Cr
Net Debt 571.14Cr 487.35Cr 447.02Cr 422.8Cr 780.23Cr 54TCr 797.55Cr 5.25TCr 2.07TCr 26TCr 2.14TCr 2.1TCr 91TCr -193.79Cr -165.36Cr -151.67Cr -143.46Cr -264.74Cr -18TCr -270.61Cr -1.78TCr -701.64Cr -8.71TCr -726.83Cr -711.88Cr -31TCr
* Estimated data More financial data

Company Profile

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Sector
Pharmaceuticals
More about the company

Quotes

Date Price Change Volume
23/26/23 132.90 $ -0.29% 66,94,616
21/26/21 133.29 $ -1.90% 60,70,570
20/26/20 135.87 $ -1.29% 38,71,215
17/26/17 137.64 $ -0.66% 73,45,882
16/26/16 138.55 $ -0.87% 34,32,531

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
133.29USD
Average target price
158.36USD
Spread / Average Target
+18.81%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GILD Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition